Advertisement

Topics

EMA grants PRIME designation for Mereo’s BPS-804 to treat osteogenesis imperfecta

02:47 EST 14 Nov 2017 | Pharmaceutical Business Review

Mereo BioPharma Group’s BPS-804 has been granted PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA) for the treatment of osteogenesis imperfecta (OI), or "brittle bone disease."

Original Article: EMA grants PRIME designation for Mereo’s BPS-804 to treat osteogenesis imperfecta

NEXT ARTICLE

More From BioPortfolio on "EMA grants PRIME designation for Mereo’s BPS-804 to treat osteogenesis imperfecta"

Advertisement
Quick Search
Advertisement
Advertisement